RxDoctor Payments Data

David Rosenblum, MD

Pain Medicine · Brooklyn, NYNPI 1043309040

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Clarius Mobile Health Corp. at 40.6% of the total. Among pain medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$105,300in general payments, 2019–2025

Across 178 payments — averaging $591.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Clarius Mobile Health Corp.$43K
  • SPR Therapeutics, Inc$23K
  • Pfizer$16K
  • Scilex Pharmaceuticals Inc.$10K
  • Nalu Medical, Inc.$3K
  • Pajunk Medical Systems, LP$3K
  • plus $7K from 28 others

What the payments were for

  • Consulting fees$29,13028%
  • Speaking & faculty fees$56,51254%
  • Travel & lodging$4,8685%
  • Food & beverage$14,70314%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,300 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$337,672
Medicare patients
408
Services billed
9,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl14$16,586
Xtampza ErOxycodone Myristate11$6,482
Fentanyl42$4,439
Pregabalin151$4,304
ZtlidoLidocaine11$4,104
Oxycodone Hcl123$3,550
Lidocaine51$2,902
Diclofenac Sodium14$2,454
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen117$2,201
Gabapentin89$992
Hydromorphone Hcl45$773
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$595
Morphine Sulfate ErMorphine Sulfate22$588
Tizanidine Hcl32$449
Baclofen54$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$128$23,06825 claims
Scilex Pharmaceuticals Inc.Ztlido$10,236$4,10411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.

Other pain medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →